Basilea Announces Change in its Management Structure
Basilea Pharmaceutica announced that Ronald Scott has been appointed has been appointed Chief Operating Officer (COO) of Basilea Pharmaceutica International.
Ronald Scott was appointed Chief Financial Officer at the company's inception. In addition to finance, business development, investor relations and public relations, he now assumes responsibility for commercial activities, manufacturing and corporate services with the respective departments retaining their heads.
He will continue as ad interim Chief Financial Officer. In line with Basilea's strategic focus to bring innovative new drugs to the market, research and development, including Basilea's operations in China, will continue to report directly to Chief Executive Officer, Dr. Anthony Man.
Anthony Man commented: "Ron has demonstrated his management skills infinance and business development as attested by Basilea's significant transactions achieved under his leadership. We are committed to bring innovative new medicines to patients addressing resistance and non-response to current treatment options in the hospital and specialty care setting. This change allows me to focus on our highest business priorities associated with Toctino, ceftobiprole, isavuconazole together with our exciting new Gram-negative antibiotic and anti-cancer drug development as well as on our mid-to-long term strategy to build value through R&D innovation."
The company is committed to principles of good corporate governance.Considering these evolving principles, Dr. Anthony Man and Ronald Scott, as executive board members, have decided to step down from the Board of Directors of Basilea Pharmaceutica with immediate effect. The Basilea Board of Directors is thus fully composed of non-executive board members.
